ArticleFrontiers in microbiology2025
Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry in the detection of vancomycin-resistant and-susceptible
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In recent years, the escalating prevalence of Vancomycin-resistant Methods: In this study, we conducted literature search through databases to summarize the distribution of regionally prevalent VSEfm/ VREfm characteristic peaks, and further collected mass spectrometry data from Meizhou People's Hospital (Guangdong, China) from 2021 to 2024 to explore stable characteristic peaks for both VSEfm and VREfm. Results: Through MALDI-TOF MS analysis, we identified stable characteristic peaks for both VSEfm (m/z 3299.95 ± 3.99 and m/z 6605.13 ± 7.28) and VREfm (m/z 3313.01 ± 2.76 and m/z 6631.03 ± 4.38) in the Meizhou region, with their discriminative efficacy validated by ROC curve analysis. Discussion: Our findings not only demonstrate the regional specificity of these characteristic peaks but also establish a robust methodological framework for rapid VSEfm/VREfm differentiation. This advancement holds significant promise for guiding clinical decision-making and controlling VREfm dissemination. Nevertheless, we acknowledge the necessity for ongoing technological refinement to enhance the accuracy and broader applicability of this approach in diverse clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.